Exelixis, Inc. (EXEL) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Convention Transcript

Michael Schmidt
Guggenheim Securities, LLC, Analysis Division

Welcome to this subsequent fireplace chat with Exelixis. With us at this time, we now have Mike Morrissey, President and CEO. Mike, welcome. Thanks for becoming a member of us once more.

Michael Morrissey
CEO, President & Director

Nice to be right here, Michael. Thanks for the invite. Earlier than we start, I will be making forward-looking statements. So please see our SEC filings for an outline of the dangers that we face in our enterprise.

Michael Schmidt
Guggenheim Securities, LLC, Analysis Division

Sounds good. Nice. Thanks, Mike. So Mike, there are loads of transferring components at Exelixis. You’ve got the business story with CABOMETYX. You’ve got current and upcoming information card flips for zanzalintinib, your key pipeline product, and you’ve got an evolving early-stage pipeline. And so earlier than we bounce into Q&A, might you simply present us with a fast introduction and contextualize the place Exelixis stands as an organization at this time?

Michael Morrissey
CEO, President & Director

I would be completely happy to. Thanks. Good morning. Good to see you once more. Nice to be right here, form of a wet day in Boston. So I am going to hopefully present some illumination. Sure. So let’s discuss Exelixis. Let’s discuss earnings that we had final week, form of set the stage for all the opposite subjects and the place we’re going as we shut out ’25 heading into ’26.

We’re a midsized business stage biotech firm centered completely in oncology. We have now form of ridden the curler coaster of ups and downs over the past 25 years, the final 10 years by way of how we have been capable of navigate